- Home
- RECT vs CTSO Comparison
RECT vs CTSO Comparison
Compare RECT & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RECT
- CTSO
- Stock Information
- Founded
- RECT 1997
- CTSO 1997
- Country
- RECT Singapore
- CTSO United States
- Employees
- RECT N/A
- CTSO N/A
- Industry
- RECT
- CTSO Medical/Dental Instruments
- Sector
- RECT
- CTSO Health Care
- Exchange
- RECT Nasdaq
- CTSO Nasdaq
- Market Cap
- RECT 66.1M
- CTSO 68.2M
- IPO Year
- RECT 2024
- CTSO N/A
- Fundamental
- Price
- RECT $4.67
- CTSO $0.84
- Analyst Decision
- RECT
- CTSO Buy
- Analyst Count
- RECT 0
- CTSO 2
- Target Price
- RECT N/A
- CTSO $5.50
- AVG Volume (30 Days)
- RECT 9.6K
- CTSO 149.4K
- Earning Date
- RECT 03-27-2025
- CTSO 05-14-2025
- Dividend Yield
- RECT N/A
- CTSO N/A
- EPS Growth
- RECT N/A
- CTSO N/A
- EPS
- RECT 0.14
- CTSO N/A
- Revenue
- RECT $33,502,767.00
- CTSO $35,332,238.00
- Revenue This Year
- RECT N/A
- CTSO $18.72
- Revenue Next Year
- RECT N/A
- CTSO $19.75
- P/E Ratio
- RECT $33.72
- CTSO N/A
- Revenue Growth
- RECT 8.42
- CTSO 15.37
- 52 Week Low
- RECT $2.70
- CTSO $0.70
- 52 Week High
- RECT $7.68
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- RECT N/A
- CTSO 41.67
- Support Level
- RECT N/A
- CTSO $0.81
- Resistance Level
- RECT N/A
- CTSO $0.90
- Average True Range (ATR)
- RECT 0.00
- CTSO 0.06
- MACD
- RECT 0.00
- CTSO 0.00
- Stochastic Oscillator
- RECT 0.00
- CTSO 32.77
About RECT Rectitude Holdings Ltd Ordinary Shares
Rectitude Holdings Ltd is principally involved in the provision of safety equipment, encompassing essential items such as personal protective clothing, hand gloves, safety footwear, and personal fall arrest systems (a system used to arrest an employee in a fall from a walking-working surface, usually consisting of a body harness, anchorage, and connector), portable fire extinguishers and traffic products such as rubber speed humps, wheel stops and wheel chocks.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.